CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
about
Prognostic value of osteopontin expression in breast cancer: A meta-analysis.Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patientsPharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.Breast cancer recurrence in relation to antidepressant use.Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment.Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese populationEffect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.A service improvement project to review prescribing information provided by general practitioners for new referrals to a UK National Health Service hospital pain clinic: potential implications of CYP2D6 enzyme inhibition.Race and ethnicity in cancer therapy: what have we learned?Cytochrome P450 pharmacogenetics in African populations: implications for public health.Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.Pharmacogenetics of chemotherapy-induced nausea and vomiting.CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy.CYP450 genotype and pharmacogenetic association studies: a critical appraisal
P2860
Q35179993-137A5707-255D-40BC-B837-B5800AF07334Q35879741-24F84C00-692A-4743-ADA1-E31A6A1D1E57Q35974459-097BDBBC-2506-4B0B-8B2E-C0255CA04712Q36489727-A16F54C9-10C8-401D-B215-D2F603BC1809Q37020150-1F9D85EC-3466-4480-9EF5-153E47651A62Q37170578-35329D9F-EFEF-4629-87A4-F4D3509EF201Q37228037-7AD3A24C-610E-401C-884C-94C48D2507B7Q37233775-0297FBF9-3663-4601-8549-F9318A39315DQ37403673-4B388A16-EED0-4AA1-B008-F72ADE2416C1Q38178095-BB1D7A07-2725-4EE0-BB29-3EE3F8273E93Q38192688-05454C4C-395D-45B7-883A-E24449313930Q38305705-417DDAF5-B2E2-4832-AE01-4E1B4C18ED66Q38330216-49E4FF5C-F243-4ADF-8C7C-85050FA2E3EDQ38668766-6F35D86E-3417-4350-B771-E9D7D9A96ABAQ38963111-8EFC56E7-2F7B-4C7E-B555-2EA744ABF2D0Q48125765-FE8E8A95-7E0E-42C8-BB61-BA974D925186Q53831501-FA9B48B7-FFD1-4ACC-80F9-F30633080154Q57585515-68CA708B-AF58-4F5D-B592-4CF78F8854B4
P2860
CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@ast
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@en
type
label
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@ast
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@en
prefLabel
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@ast
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@en
P2093
P2860
P31
P921
P1433
P1476
CYP2D6 genotype and tamoxifen ...... atic review and meta-analysis.
@en
P2093
Danny W K Lum
Michael V Holmes
Pablo Perel
P2860
P304
P356
10.1371/JOURNAL.PONE.0076648
P407
P5008
P577
2013-10-02T00:00:00Z